Assess the effect of alirocumab on ischemic and hemorrhagic stroke1
Alirocumab reduced the risk of any stroke and ischemic stroke without increasing the risk of hemorrhagic stroke in patients with ACS and dyslipidemia despite statin therapy1
The treatment effect of alirocumab on any stroke was numerically greater for patients with baseline LDL-C≥100 mg/ dL1KEY FINDINGS
Alirocumab reduced the risk of any stroke and ischemic stroke without increasing the risk of hemorrhagic stroke in patients with ACS and dyslipidemia despite statin therapy*†1
Alirocumab significantly reduced the relative risk of MACE (primary endpoint) by 15%; HR 0,85 (95% Cl 0.78, 0.93) p=0.0 003.
Incidence of any stroke, ischemic stroke, and hemorrhagic stroke in patients with ACS and dyslipidemia despite statin therapy*1
*P- values have nominal significance by hierarchical testing in the primary analysis2
†Median follow-up of 2.8 years. 44% were eligible to be followed for 3-5 years1,2
KEY FINDINGS
The treatment effect of alirocumab on any stroke was numerically greater for patients with baseline LDL-C≥1OO mg/dl 1
Stroke by baseline LDL-C category and history of CeVD1
Interaction p values: p=0.31 LDL-C, p=0.37 CeVD. CeVD included a history of carotid endarterectomy, carotid stenting, prior stroke, or TIA.1
ACS=acute coronary syndrome; CeVD=cerebrovascular disease; Cl =confidence interval; HR=hazard ratio; LDL- C=low-density lipoprotein cholesterol; RRR=relative risk reduction; TIA=transient ischemic attack.
1. Jukema JW, Zijlstra LE, Bhatt DL,et al; for the Odyssey Outcomes Investigators. Effect of alirocumab on stroke in Odyssey Outcomes. Circulation. 2019;140(25):2054-2062.
2. Schwartz G, et al. N Engl J Med 2018;379(22):2097–2107.
